Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

THE PROPHYLAXIS OF RHEUMATIC FEVER

THE PROPHYLAXIS OF RHEUMATIC FEVER Although some evidence1 tends to show that sulfanilamide is without therapeutic effect (and may even be dangerous) in the treatment of rheumatic fever, the reports of Thomas and France2 in Baltimore and of Coburn and Moore3 in New York have indicated that the drug may be of prophylactic value in preventing the recurrence of rheumatic attacks. Its experimental use for this purpose was based on the series of observations made by Coburn during the past decade, which relate rheumatic activity to the presence of hemolytic streptococcus infections of the rhinopharynx. Both groups of investigators thought that, if these infections of the throat could be prevented, rheumatic recrudescences might not occur. To accomplish this result, small doses of sulfanilamide were given daily to rheumatic subjects during the period of the year (October to June or July) in which the incidence of streptococcic infections of the pharynx is highest. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

THE PROPHYLAXIS OF RHEUMATIC FEVER

JAMA , Volume 116 (7) – Feb 15, 1941

THE PROPHYLAXIS OF RHEUMATIC FEVER

Abstract


Although some evidence1 tends to show that sulfanilamide is without therapeutic effect (and may even be dangerous) in the treatment of rheumatic fever, the reports of Thomas and France2 in Baltimore and of Coburn and Moore3 in New York have indicated that the drug may be of prophylactic value in preventing the recurrence of rheumatic attacks. Its experimental use for this purpose was based on the series of observations made by Coburn during the past decade, which relate rheumatic...
Loading next page...
 
/lp/american-medical-association/the-prophylaxis-of-rheumatic-fever-dzjIUpvxZA

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 1941 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1941.02820070046013
Publisher site
See Article on Publisher Site

Abstract

Although some evidence1 tends to show that sulfanilamide is without therapeutic effect (and may even be dangerous) in the treatment of rheumatic fever, the reports of Thomas and France2 in Baltimore and of Coburn and Moore3 in New York have indicated that the drug may be of prophylactic value in preventing the recurrence of rheumatic attacks. Its experimental use for this purpose was based on the series of observations made by Coburn during the past decade, which relate rheumatic activity to the presence of hemolytic streptococcus infections of the rhinopharynx. Both groups of investigators thought that, if these infections of the throat could be prevented, rheumatic recrudescences might not occur. To accomplish this result, small doses of sulfanilamide were given daily to rheumatic subjects during the period of the year (October to June or July) in which the incidence of streptococcic infections of the pharynx is highest.

Journal

JAMAAmerican Medical Association

Published: Feb 15, 1941

There are no references for this article.